Ciprofloxacin plus piperacillin is an equally effective regimen for empiric therapy in febrile neutropenic patients compared with standard therapy.
The purpose of this study was to test the comparative efficacy and toxicity of empiric gentamicin and ciprofloxacin, in combination with piperacillin, in febrile patients with treatment-induced neutropenia. Fifty patients were prospectively randomized to receive piperacillin plus gentamicin (PG), and 46 were randomized to receive piperacillin plus ciprofloxacin (PC). The groups were similar in age, sex, diagnosis, duration of neutropenia, and incidence of positive cultures. The two antibiotic regimens were associated with comparable rates of defervescence in the patients with gram-positive bacteremia. In the patients with gram-negative bacteremia and those with negative cultures, however, defervescence was more prompt in the PC group. In particular, 27% of the culture-negative patients on PC, compared to only 5% of those on PG, defervesced within 72 hr (P = 0.015). Because of the more prompt defervescence in the PC group, amphotericin B was used less frequently; 78% of the patients on PG compared with only 56% of those on PC were started on amphotericin B (P = 0.025). PC is an effective alternative to the more traditional PG for treatment of febrile neutropenic hosts who have not been given prophylactic quinolones. More important, PC appears to hasten defervescence compared with PG, especially in culture-negative patients and those with gram-negative bacteremia, and may decrease the necessity of additional antimicrobial agents such as amphotericin B.
Department of Medicine, Hematology Unit, University of Rochester School of Medicine and Dentistry, New York, USA. Jennifer_Griggs@urmc.rochester.edu
J J
JJ
Griggs
E A
EA
Blair
J R
JR
Norton
J M
JM
Rowe
W R
WR
Flesher
R F
RF
Betts
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D001424:Bacterial Infections / Q000097:blood; D002939:Ciprofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005334:Fever / Q000188:drug therapy*; D005839:Gentamicins / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009181:Mycoses / Q000097:blood; D009503:Neutropenia / Q000188:drug therapy*; D010878:Piperacillin / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D013997:Time Factors; D014640:Vancomycin / Q000627:therapeutic use
D005839:Gentamicins; D002939:Ciprofloxacin; D014640:Vancomycin; D000666:Amphotericin B; D010878:Piperacillin